Stereotaxis (STXS) Projected to Post Earnings on Tuesday

Stereotaxis (NYSEAMERICAN:STXS) will likely be releasing its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect Stereotaxis to announce earnings of ($0.0533) per share and revenue of $9.60 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

Stereotaxis (NYSEAMERICAN:STXS) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). Stereotaxis had a negative return on equity of 130.84% and a negative net margin of 74.24%. The business had revenue of $7.67 million during the quarter, compared to the consensus estimate of $8.35 million. On average, analysts expect Stereotaxis to post ($0.22) EPS for the current fiscal year and ($0.17) EPS for the next fiscal year.

Stereotaxis Stock Performance

NYSEAMERICAN:STXS traded down $0.04 during mid-day trading on Tuesday, hitting $0.84. The company had a trading volume of 123,079 shares, compared to its average volume of 593,364. Stereotaxis has a fifty-two week low of $0.81 and a fifty-two week high of $2.89. The business’s fifty day moving average is $1.21 and its two-hundred day moving average is $1.71. The firm has a market cap of $84.47 million, a P/E ratio of -3.51 and a beta of 1.37.

Analysts Set New Price Targets

Several research firms have recently issued reports on STXS. TD Cowen decreased their target price on Stereotaxis from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Citigroup reiterated an “outperform” rating on shares of Stereotaxis in a research report on Thursday, August 27th. Finally, Citizens Jmp reduced their price objective on shares of Stereotaxis from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 27th. Five equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $3.50.

About Stereotaxis

Stereotaxis, Inc develops robotic technologies for minimally invasive endovascular procedures, with a primary focus on cardiac electrophysiology. Its systems use magnetic navigation and specialized software to help physicians control guidewires and catheters during procedures such as the treatment of cardiac arrhythmias.

The company’s product portfolio includes the Genesis Robotic Magnetic Navigation System, which is designed to provide precise catheter movement and navigation within the heart.